Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Sponsor: Memorial Sloan Kettering Cancer Center
This PHASE2 trial investigates Brain and Central Nervous System Tumors and Intraocular Melanoma and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 14 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2023 — May 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .